UDG Healthcare accepts higher £2.8bn takeover bid
US private equity firm Clayton, Dubilier & Rice said the 1,080p-a-share bid is its final offer and now has the support of large investors.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The board of private healthcare business UDG has accepted an increased takeover bid valuing the company at £2.8 billion after some shareholders claimed an earlier bid was “opportunistic”.
US private equity firm Clayton, Dubilier & Rice said the 1,080p-a-share bid is its final offer and now has the support of large investors.
Shareholders Allianz and Kabouter, making up 11.41% of total investors, have written letters of support in favour of the offer.
The company added that other institutional investors have also indicated their willingness to vote for the deal.
The latest price is higher than the 1,023p-a-share offer made last month.
Allianz had called the original offer “opportunistic” and said it “significantly undervalues UDG and its prospects”.
UDG directors said they believe the company is “well-positioned for future continued success and that the long-term prospects of the group are strong as an independent listed entity.
“Nevertheless, the UDG directors recognise that uncertainties exist, many of which are beyond UDG’s control.”
A vote on the deal will take place next month at the company’s head office in Dublin unless an outside bid is received, in which case Clayton, Dubilier & Rice may increase its offer.
UDG operates two divisions and employs around 9,000 workers across 29 countries.
Its largest division, Ashfield is a global healthcare services business working in advisory, marketing and communications.
The other division, Sharp is a contract packaging, clinical, manufacturing and technology services business.
The group was built by Liam FitzGerald, who was chief executive for 16 years until 2016.
He is now an adviser in Europe to Clayton, Dubilier & Rice and last year became chairman of healthcare marketing and services company Huntsworth, after the private equity firm bought it for £575 million last May.
The new owners plan to merge Huntsworth with Ashfield.
Clayton, Dubilier & Rice recently hit the headlines for making a £5.5 billion bid for supermarket Morrisons, although the company said it significantly undervalues the business.